CDMO vs CMO vs CRO — What's the Difference?
The three abbreviations that get confused most often in biopharma outsourcing — definitions, scope, and when to use which.
CRO (Contract Research Organization) supports drug discovery and clinical trial execution — the R and early D of R&D. CMO (Contract Manufacturing Organization) makes the drug — traditionally offering manufacturing capacity only. CDMO (Contract Development and Manufacturing Organization) is a CMO that also does process development, analytics development, and scale-up — a fuller manufacturing partnership. In practice, most modern contract manufacturers position as CDMO regardless of actual development capability; the distinction is now more about scope of engagement than any hard capability line. Choose by what you actually need done: research and trials → CRO; manufacturing only (you have process locked) → CMO; process development + manufacturing → CDMO.
CRO — Contract Research Organization
CROs support the research and clinical development side of drug development. Their scope typically covers: preclinical services (toxicology, DMPK, safety pharmacology, bioanalytical), clinical trial operations (site selection, patient recruitment, monitoring, data management, biostatistics), and regulatory affairs support (protocol design, IND/CTA preparation, submissions). The largest CROs — IQVIA, Labcorp Drug Development, Parexel, ICON, PPD — operate as end-to-end trial partners for pharma sponsors.
CROs generally do NOT manufacture GMP drug supply. That's the CMO/CDMO domain. A sponsor may work with both a CRO (for trial operations) and a CDMO (for clinical drug supply) simultaneously — they're complementary, not overlapping.
CROs generally do NOT manufacture GMP drug supply. That's the CMO/CDMO domain. A sponsor may work with both a CRO (for trial operations) and a CDMO (for clinical drug supply) simultaneously — they're complementary, not overlapping.
CMO — Contract Manufacturing Organization
CMO is the traditional term for a contract manufacturer that makes drug product or drug substance under GMP for a sponsor. Historical CMOs offered manufacturing capacity — the sponsor arrived with a locked process and the CMO executed it. The CMO's value was scale, capacity, and cost-efficient production; process development was the sponsor's responsibility.
The pure CMO model is now rare. Most contract manufacturers have expanded into some form of process development capability, either to differentiate on service depth or because sponsors increasingly demand development support. The term "CMO" is still used, especially for large-molecule work (sometimes "BMO" for biologics), but most current contract manufacturers brand themselves as CDMOs.
The pure CMO model is now rare. Most contract manufacturers have expanded into some form of process development capability, either to differentiate on service depth or because sponsors increasingly demand development support. The term "CMO" is still used, especially for large-molecule work (sometimes "BMO" for biologics), but most current contract manufacturers brand themselves as CDMOs.
CDMO — Contract Development and Manufacturing Organization
CDMO extends the CMO model to include process development, analytics development, and scale-up — the development work needed to take a program from early clinical process to commercial readiness. A CDMO engagement typically includes some or all of: cell-line development, process development and optimization, analytics method development and validation, formulation development, scale-up runs, comparability studies, and finally GMP manufacturing at clinical or commercial scale.
In practice, "CDMO" is the dominant industry term today — most contract manufacturers brand as CDMOs regardless of actual development depth. That means the label alone doesn't tell you what capability the CDMO actually has. Diligence at RFP on specific development capability (which assays they've developed for programs like yours, which processes they've scaled from small-scale to commercial) is essential — the "D" varies widely across CDMOs sharing the same brand category.
In practice, "CDMO" is the dominant industry term today — most contract manufacturers brand as CDMOs regardless of actual development depth. That means the label alone doesn't tell you what capability the CDMO actually has. Diligence at RFP on specific development capability (which assays they've developed for programs like yours, which processes they've scaled from small-scale to commercial) is essential — the "D" varies widely across CDMOs sharing the same brand category.
Which one do you need?
The practical decision depends on scope: drug discovery or clinical trial execution → CRO. Manufacturing only, process is locked → CMO (or a CDMO used for manufacturing scope only). Process development + manufacturing → CDMO. Programs often engage all three at different stages: CROs for preclinical + clinical trial operations, a CDMO for drug supply, and sometimes a separate specialty CRO for late-stage bioanalytical work.
Also note the newer variants: CRDMO (Contract Research, Development, and Manufacturing Organization) is used by fully-integrated players like WuXi AppTec that offer end-to-end services from discovery through commercial manufacturing. CTDMO (Contract Testing, Development, and Manufacturing Organization) adds standalone analytical testing services. These are useful positioning distinctions but don't fundamentally change the CDMO framework — they're broader scopes of the same integrated-partner concept.
Also note the newer variants: CRDMO (Contract Research, Development, and Manufacturing Organization) is used by fully-integrated players like WuXi AppTec that offer end-to-end services from discovery through commercial manufacturing. CTDMO (Contract Testing, Development, and Manufacturing Organization) adds standalone analytical testing services. These are useful positioning distinctions but don't fundamentally change the CDMO framework — they're broader scopes of the same integrated-partner concept.
Frequently Asked
Is CDMO the same as CMO?
Not exactly. CMO (Contract Manufacturing Organization) traditionally means manufacturing capacity only, with the sponsor arriving with a locked process. CDMO (Contract Development and Manufacturing Organization) adds process development, analytics development, and scale-up — the fuller manufacturing partnership. In practice, most contemporary contract manufacturers brand as CDMOs regardless of actual development capability depth.
Do I need a CRO and a CDMO?
Usually yes, at different stages. CROs handle preclinical research and clinical trial operations; CDMOs manufacture clinical and commercial drug supply. A sponsor running a Phase 2 program typically has a CRO for trial operations AND a CDMO for drug substance/drug product supply. The two engagements are complementary, not overlapping.
What is a CRDMO?
Contract Research, Development, and Manufacturing Organization. A fully-integrated player offering end-to-end services from drug discovery through commercial manufacturing — the term is most associated with WuXi AppTec's business model. Practically, a CRDMO is a combined CRO + CDMO relationship under one contract.
Which is right for a small biotech?
For most small biotechs, a specialized CRO for early clinical work and a specialized CDMO for clinical drug supply is the standard path — the discipline separation lets you shortlist each independently on the criteria that matter for that scope. Larger biotechs or programs at scale sometimes consolidate into a CRDMO relationship for coordination advantages. See our CDMO selection framework for CDMO-specific shortlisting guidance.